Z-L-正缬氨酸 | 21691-44-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 缬氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Z-L-正缬氨酸
• 中文别名: 苄氧羰酰基正缬氨酸；苄氧羰基-L-正缬氨酸；CBZ-L-正缬氨酸；Cbz-L-正缬氨酸；N-苄氧羰基-L-正缬氨酸；N-CBZ-L-正缬氨酸
• 英文名称: Z-L-norvaline
• 英文别名: N-benzyloxycarbonyl-L-norvaline；2S-2-benzyloxycarbonylamino-2-propyl-acetic acid；(S)-2-(((Benzyloxy)carbonyl)amino)pentanoic acid；(2S)-2-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 21691-44-1
• 化学式: C₁₃H₁₇NO₄
• 分子量: 251.282
• InChiKey: NSJDRLWFFAWSFP-NSHDSACASA-N

物化性质

• 沸点：
  439.4±38.0 °C(Predicted)
• 密度：
  1.184±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 稳定性/保质期：

  在常温常压下稳定。

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储于室温下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-Nva-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-Nva-OH
CAS number: 21691-44-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H17NO4
Molecular weight: 251.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途： 生化研究

反应信息

• 作为反应物：
  描述：

  Z-L-正缬氨酸 在 palladium on activated charcoal manganese(IV) oxide 、 sodium tetrahydroborate 、 lithium aluminium tetrahydride 、 氢气 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 乙醚 为溶剂， 反应 16.0h， 生成 毒芹碱
  参考文献：
  名称：

  从β-氨基酸方便地原位合成非外消旋的N-保护的β-氨基醛。在维蒂希反应和杂环合成中的应用

  摘要：

  源自非外消旋β-氨基酸的N - Z -γ-氨基醇在乙腈中被二氧化锰平滑氧化，得到醛，这些醛可在Wittig反应中与羰基取代的磷烷原位捕获。描述了该方法在生物碱（S）-（+）- N -BOC-coniie，（S）-（-）-coniceine和胡椒碱前体的合成中的应用。

  DOI：

  10.1016/s0040-4039(98)02573-8
• 作为产物：
  描述：

  L-正缬氨酸 在 氯甲酸苄酯 作用下， 生成 Z-L-正缬氨酸
  参考文献：
  名称：

  Izumiya; Yamashita, Journal of Biochemistry, 1959, vol. 46, p. 19,21

  摘要：

  DOI：

文献信息

• Protease inhibitors
  申请人：——

  公开号：US20020049316A1

  公开（公告）日：2002-04-25

  The present invention provides compounds of formula (I) which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia or malignancy; and metabolic bone disease therewith.

  本发明提供了一种公式（I）的化合物，其抑制蛋白酶，包括卡特普辛K，以及这些化合物的药物组合物，以及治疗骨量过度流失或软骨或基质降解疾病的方法，包括骨质疏松症；牙龈疾病，包括牙龈炎和牙周炎；关节炎，更具体地说是骨关节炎和类风湿关节炎；帕吉特病；高钙血症或恶性肿瘤；以及代谢性骨病。
• Polypeptides. Part VIII. Variations of the aspartyl position in the C-terminal tetrapeptide amide sequence of the gastrins
  作者：H. Gregory、J. S. Morley、J. M. Smith、M. J. Smithers

  DOI：10.1039/j39680000715

  日期：——

  The synthesis is described of analogues of L-tryptophyl-L-methionyl-L-aspartyl-L-phenylalanine amide (the C-terminal sequence of the gastrins), and its N-benzyloxycarbonyl or N-t-butoxycarbonyl derivatives, wherein the aspartyl residue has undergone replacement by alanyl, β-aspartyl, asparaginyl, cysteinyl, glutamyl, glycyl, lysyl, norvalyl, ornithyl, seryl, threonyl, and other amino-acyl residues

  描述了L-色氨酸-L-甲硫酰基-L-天冬氨酰-L-苯丙氨酸酰胺（胃泌素的C-末端序列）及其N-苄氧羰基或N-叔丁氧羰基衍生物的类似物的合成，其中天冬氨酰残基已被丙氨酰基，β-天冬氨酰，天冬酰胺基，半胱氨酰基，谷氨酰基，甘氨酰基，赖氨酰基，降冰片酰基，鸟氨酸残基，丝氨酰基，苏氨酰基和其他氨基酰基残基取代。
• Thiadiazole amide MMP inhibitors
  申请人：——

  公开号：US05830869A1

  公开（公告）日：1998-11-03

  The present invention provides novel thiadiazole amide derivatives represented by formula I ##STR1## The compounds of the present invention inhibit various enzymes from the matrix metalloproteinase family, predominantly stromelysins, and hence are useful for the treatment of matrix metallo endoproteinase diseases such as osteoarthritis, rheumatoid arthritis, septic arthritis, osteopenias such as osteoporosis, tumor metastasis, periodontitis, gingivitis, corneal ulceration, dermal ulceration, gastric ulceration, inflammation and other diseases related to connective tissue degradation.

  本发明提供了由式I表示的新型噻二唑酰胺衍生物。本发明的化合物抑制来自基质金属蛋白酶家族的各种酶，主要是胶原酶，因此对于治疗基质金属蛋白酶疾病如骨关节炎、类风湿性关节炎、化脓性关节炎、骨质疏松症如骨质疏松症、肿瘤转移、牙周炎、牙龈炎、角膜溃疡、皮肤溃疡、胃溃疡、炎症和其他与结缔组织降解相关的疾病具有用处。
• Effective Methods for the Synthesis ofN-Methylβ-Amino Acids from All Twenty Commonα-Amino Acids Using 1,3-Oxazolidin-5-ones and 1,3-Oxazinan-6-ones
  作者：Andrew B. Hughes、Brad E. Sleebs

  DOI：10.1002/hlca.200690235

  日期：2006.11

  N-Methyl β-amino acids are generally required for application in the synthesis of potentially bioactive modified peptides and other oligomers. Previous work highlighted the reductive cleavage of 1,3-oxazolidin-5-ones to synthesise N-methyl α-amino acids. Starting from α-amino acids, two approaches were used to prepare the corresponding N-methyl β-amino acids. First, α-amino acids were converted to

  应用N-甲基β-氨基酸通常是潜在合成具有生物活性的修饰的肽和其他寡聚体的应用。先前的工作强调了1，3-恶唑烷-5-酮的还原裂解以合成N-甲基α-氨基酸。从α-氨基酸开始，使用两种方法来制备相应的N-甲基β-氨基酸。首先，α -氨基酸转化为Ñ甲基α -氨基酸由所谓的“-1,3-恶唑-5-酮的策略”，将它们再由同系阿恩特-艾斯特方法，得到Ñ-protected Ñ -甲基β -氨基酸选自20种常见衍生α -氨基酸。这些化合物的制备产率为23–57％（相对于N-甲基α-氨基酸）。在第二种方法中，可以通过Arndt–Eistert方法将12个N保护的α-氨基酸直接同源，然后将所得的β-氨基酸以30–45％的产率转化为1,3-恶二嗪-6-酮。 。最后，还原裂解以41–63％的收率提供了所需的N-甲基β-氨基酸。
• Enantioselective inclusion of pyrene-1-sulfonate salts of α-amino acids with crystals of α-cyclodextrin
  作者：Ikuko Miyoshi、Yuichi Kitamoto、Tetsuya Maeda、Naoya Morohashi、Tetsutaro Hattori

  DOI：10.1016/j.tet.2020.131100

  日期：2020.4

  Enantioselective inclusion of α-amino acids with crystals of α-cyclodextrin (α-CD) has been achieved by converting the amino acids into sulfonate salts with pyrene-1-sulfonic acid (PyS). For example, crystals of α-CD selectively include l-leucine/PyS (1:1) salt in a host/guest ratio of ∼1 with 92%ee from a solution of the racemic salt in ethanol/N-methylformamide (91:9) at 40 °C. Under conditions optimized

  的对映选择性包含α -氨基羧酸与晶体α环糊精（α -CD）已经由氨基酸转化成磺酸盐与芘-1-磺酸（PYS）来实现的。例如，α -CD的晶体选择性地含有约1的主体/客体比率的1-亮氨酸/ PyS（1：1）盐和来自消旋盐的乙醇/ N溶液的92％ee-甲基甲酰胺（91：9）在40°C下。在针对单个氨基酸优化的条件下，缬氨酸，苯丙氨酸和蛋氨酸的PyS盐也具有良好的对映选择性（最高86％ee）。对亮氨酸/ PyS盐包合物的机理研究表明，对映选择性源于D和1-亮氨酸/ PyS盐与α -CD包合物在晶体中稳定性的差异。